針對嵌合體分子的蛋白質分解市場規模、佔有率和成長分析：按類型、按適應症、按技術、按應用、按最終用戶、按地區 - 2025-2032 年行業預測

2023年，蛋白水解靶向嵌合體分子（PROTAC）的全球市場規模為1.2546億美元，從2024年的1.3826億美元成長到2032年的3.007億美元，預測期（2025-2032）預計複合年成長率為10.2%。

PROTAC（蛋白水解靶向嵌合體）是一種突破性的治療方法，透過選擇性和特異性分解而不是標準抑制來靶向先前「無法治療」的蛋白質。透過繞過傳統的結合限制並利用與不同蛋白質結構域結合的配體，它們有效地結合困難的蛋白質，例如轉錄因子和激酶。此方法可以更全面、更持續地抑制標靶蛋白。例如，針對雄性激素受體的藥物可抑制前列腺癌細胞的增殖，而靶向 BCL-2 的藥物可誘導各種癌症的細胞凋亡。儘管取得了有希望的發展，但挑戰仍然存在，特別是在設計有效結合的配體和最佳化藥物動力學特性以增強體內性能方面。

目錄

介紹

• 研究目的
• 調查範圍
• 定義

調查方法

• 資訊採購
• 二手資料和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制因素和挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 價格分析

按類型分類的全球蛋白水解靶向嵌合體分子 (PROTAC) 市場規模

• 市場概況
• 小分子PROTAC
• 胜肽PROTAC
• 以蛋白質為基礎的 PROTAC

按適應症分類的全球蛋白質分解靶向嵌合體分子 (PROTAC) 市場規模

• 市場概況
• 癌症
• 自體免疫疾病
• 神經退化性疾病

按技術分類的全球蛋白水解靶向嵌合體分子 (PROTAC) 市場規模

• 市場概況
• 雙功能性
• 單價

全球蛋白質分解靶向嵌合體分子 (PROTAC) 市場規模（按應用）

• 市場概況
• 腫瘤學
• 神經退化性疾病
• 發炎性疾病

按最終用戶分類的全球蛋白水解嵌合體分子 (PROTAC) 市場規模

• 市場概況
• 製藥公司
• 學術研究所
• 合約調查機構（Cros）

全球蛋白質分解靶向嵌合體分子（PROTAC）市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東/非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲

競爭資訊

• 前5名企業對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分類的佔有率分析
  • 收益與前一年同期比較（2022-2024）

主要企業簡介

• Arvinas（USA）
• C4 Therapeutics（USA）
• Kymera Therapeutics（USA）
• Nurix Therapeutics（USA）
• Bristol Myers Squibb（USA）
• Pfizer（USA）
• Sanofi（France）
• AstraZeneca（UK）
• Roche（Switzerland）
• Olema Pharmaceuticals（USA）
• Radius Health（USA）
• Loxo Oncology（USA）
• Amphista Therapeutics（UK）
• Monte Rosa Therapeutics（USA）
• Dunad Therapeutics（UK）
• Ranok Therapeutics（China）
• Ubiquigent（UK）
• Origami Therapeutics（USA）
• Treeline Biosciences（USA）
• Entact Bio（USA）

結論和建議

Global Proteolysis-targeting chimeric molecules (PROTACs) Market size was valued at USD 125.46 million in 2023 and is poised to grow from USD 138.26 million in 2024 to USD 300.7 million by 2032, growing at a CAGR of 10.2% during the forecast period (2025-2032).

PROTACs (Proteolysis Targeting Chimeras) represent a groundbreaking therapeutic approach, targeting previously "undruggable" proteins through selective and specific degradation rather than standard inhibition. They effectively engage with challenging proteins, such as transcription factors and kinases, by utilizing ligands that bind to distinct protein domains, circumventing traditional binding limitations. This method facilitates a more comprehensive and lasting inhibition of target proteins. Preclinical studies have demonstrated significant efficacy, showing PROTACs' potential in cancer therapies; for instance, one targeting the androgen receptor inhibited prostate cancer cell growth, while another targeting BCL-2 induced apoptosis in various cancers. Despite promising developments, challenges remain, particularly in designing ligands for effective binding and optimizing pharmacokinetic properties for enhanced in vivo performance.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Proteolysis-Targeting Chimeric Molecules (Protacs) market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Proteolysis-Targeting Chimeric Molecules (Protacs) Market Segmental Analysis

Global Proteolysis-targeting chimeric molecules (PROTACs) Market is segmented by Type, Indication, Technology, Application, End-User and region. Based on Type, the market is segmented into Small Molecule PROTACs, Peptide PROTACs and Protein-Based PROTACs. Based on Indication, the market is segmented into Cancer, Autoimmune Diseases and Neurodegenerative Disorders. Based on Technology, the market is segmented into Bifunctional and Monovalent. Based on Application, the market is segmented into Oncology, Neurodegenerative Diseases and Inflammatory Diseases. Based on End-User, the market is segmented into Pharmaceutical Companies, Academic and Research Institutions and Contract Research Organizations (Cros). Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Proteolysis-Targeting Chimeric Molecules (Protacs) Market

A key driving force behind the advancement of Proteolysis-Targeting Chimeric Molecules (PROTACs) is the growing demand for enhanced target specificity in drug development. Traditional small-molecule drugs typically exhibit a lack of specificity, often affecting multiple proteins and resulting in unintended side effects and potential toxicity. In contrast, PROTACs are meticulously engineered to hone in on a particular protein or even a specific domain within that protein. This heightened level of target specificity significantly mitigates the risk of off-target consequences, thereby improving the safety profile of these molecules and paving the way for innovative treatments for previously challenging diseases.

Restraints in the Global Proteolysis-Targeting Chimeric Molecules (Protacs) Market

One significant challenge facing the Proteolysis-Targeting Chimeric Molecules (PROTACs) market is the complexity of designing and synthesizing compounds that are both effective and safe. Achieving the right balance between the ligands' affinity for their specific targets and the potency of the E3 ligase recruiting ligand is crucial, yet difficult. Multiple factors, including steric hindrance, charge, and solubility, can affect ligand binding affinity. Furthermore, selecting the appropriate E3 ligase is critical, as certain E3 ligases may exhibit promiscuous activity, which can result in undesired off-target effects, complicating the development of reliable PROTAC therapeutics.

Market Trends of the Global Proteolysis-Targeting Chimeric Molecules (Protacs) Market

The Global Proteolysis-Targeting Chimeric Molecules (PROTACs) market is witnessing significant growth, driven by the escalating adoption of this innovative technology in drug discovery and development. By focusing on the degradation of disease-causing proteins rather than mere inhibition, PROTACs present a transformative approach that enhances therapeutic efficacy, particularly for diseases resistant to conventional treatments. As pharmaceutical companies and research institutions intensify their exploration of PROTACs, the market is experiencing a surge in research and development activities. This trend is poised to revolutionize treatment paradigms, attracting attention from investors and stakeholders, further propelling the PROTACs market towards expansive growth.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Proteolysis-targeting chimeric molecules (PROTACs) Market Size by Type & CAGR (2025-2032)

• Market Overview
• Small Molecule PROTACs
• Peptide PROTACs
• Protein-Based PROTACs

Global Proteolysis-targeting chimeric molecules (PROTACs) Market Size by Indication & CAGR (2025-2032)

• Market Overview
• Cancer
• Autoimmune Diseases
• Neurodegenerative Disorders

Global Proteolysis-targeting chimeric molecules (PROTACs) Market Size by Technology & CAGR (2025-2032)

• Market Overview
• Bifunctional
• Monovalent

Global Proteolysis-targeting chimeric molecules (PROTACs) Market Size by Application & CAGR (2025-2032)

• Market Overview
• Oncology
• Neurodegenerative Diseases
• Inflammatory Diseases

Global Proteolysis-targeting chimeric molecules (PROTACs) Market Size by End-User & CAGR (2025-2032)

• Market Overview
• Pharmaceutical Companies
• Academic and Research Institutions
• Contract Research Organizations (Cros)

Global Proteolysis-targeting chimeric molecules (PROTACs) Market Size & CAGR (2025-2032)

• North America (Type, Indication, Technology, Application, End-User)
  • US
  • Canada
• Europe (Type, Indication, Technology, Application, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Indication, Technology, Application, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Indication, Technology, Application, End-User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Indication, Technology, Application, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Arvinas (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• C4 Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kymera Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nurix Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Olema Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Radius Health (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Loxo Oncology (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amphista Therapeutics (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Monte Rosa Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dunad Therapeutics (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ranok Therapeutics (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ubiquigent (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Origami Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Treeline Biosciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Entact Bio (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations